I noticed some in this recent cohort had 177lu and 255ac. I can see how this would've played a part in how well patients would've responded to cu67. If 255ac isn't approved, why would the FDA consider having 255ac as a prereq for P3?
Despite all this, 44% had PSA over 50% on a single dose(pluvicto was ~46%).
Ann: Theranostic prostate cancer trial advances to multi-dose, page-21
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.09 |
Change
-0.210(4.88%) |
Mkt cap ! $1.272B | |||
| Open | High | Low | Value | Volume |
| $4.30 | $4.30 | $4.08 | $3.493M | 835.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7459 | $4.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.12 | 9361 | 1 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.10 |
Change
-0.210 ( 4.15 %) |
||||
| Open | High | Low | Volume | ||
| $4.17 | $4.29 | $4.08 | 50363 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| CU6 (ASX) Chart |